Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 1, 2004, Pages 202-208

  Al Huniti, N H ^a   Widness, J A ^b   Schmidt, R L ^b   Veng Pedersen, P ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IODINE 125; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANIMAL MODEL; ARTICLE; ERYTHROPOIESIS; FLOW CYTOMETRY; HEMOGLOBIN DETERMINATION; HORMONAL REGULATION; NONHUMAN; PHLEBOTOMY; PRIORITY JOURNAL; RETICULOCYTE COUNT; SHEEP;

ACUTE DISEASE; ANEMIA; ANIMALS; ERYTHROPOIETIN; HEMOGLOBINS; KINETICS; PHLEBOTOMY; RETICULOCYTES; SHEEP; SOCIAL CONTROL, FORMAL;

EID: 3042548807     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.066027     Document Type: Article

References (43)

1. Abbrecht PH and Littell JK (1972) Plasma erythropoietin in men and mice during acclimatization to different altitudes. J Appl Physiol 32:54-58.
2. Akaike H (1974) Automatic control: a new look at the statistical model identification. IEEE Transactions 19:716-723.
3. Bauer C and Kurtz A (1989) Oxygen sensing in the kidney and its relation to erythropoietin production. Annu Rev Physiol 51:845-856.
4. Beck I, Ramirez S, Weinmann R, and Caro J (1991) Enhancer element at the 3′-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. J Biol Chem 266:15563-15566.
5. Bondurant MC and Koury MJ (1986) Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol 6:2731-2733.
6. Chapel SH, Veng-Pedersen P, Schmidt RL, and Widness JA (2001) Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 29:425-431.
7. Eckardt KU (1995) The ontogeny of the biological role and production of erythropoietin. J Perinat Med 23:19-29.
8. Eckardt KU, Dittmer J, Neumann R, Bauer C, and Kurtz A (1990) Decline of erythropoietin formation at continuous hypoxia is not due to feedback inhibition. Am J Physiol 258:F1432-F1437.
9. Fried W and Barone-Varelas J (1984) Regulation of the plasma erythropoietin level in hypoxic rats. Exp Hematol 12:706-711.
10. Fried W, Barone-Varelas J, Barone T, and Helfgott M (1980) Extraction of erythropoietin from kidneys. Exp Hematol 8 (Suppl 8):41-51.
11. Goldberg MA, Gaut CC, and Bunn HF (1991) Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood 77:271-277.
12. Gupta M and Goldwasser E (1996) The role of the near upstream sequence in hypoxia-induced expression of the erythropoietin gene. Nucleic Acids Res 24:4768-4774.
13. Hutchinson MF and deHoog FR (1985) Smoothing noise data with spline functions. Numer Math 47:99-106.
14. Juul S (2002) Erythropoietin in the central nervous system and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 438:36-42.
15. Juul SE, Ledbetter DJ, Joyce AE, Dame C, Christensen RD, Zhao Y, and DeMarco V (2001) Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 49:182-189.
16. Juul SE, Yachnis AT, and Christensen RD (1998) Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235-249.
17. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, and Sugiyama Y (1997) Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283:520-527.
18. Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, and Sugiyama Y (1998) Pharmacokinetics of erythropoietin in genetically anemic mice. Drug Metab Dispos 26:126-131.
19. Kato Y, Seita T, Kuwabara T, and Sugiyama Y (1996) Kinetics analysis of receptor-mediated edocytosis (RME) of proteins and peptides: use of RME as a drug delivery system. J Control Release 39:191-200.
20. Levy D (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252.
21. Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodynam 28:507-532.
22. Maxwell PH, Pugh CW, and Ratcliffe PJ (1993) Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: evidence for a widespread oxygensensing mechanism. Proc Natl Acad Sci USA 90:2423-2427.
23. Miller ME and Howard D (1979) Modulation of Erythropoietin Concentrations by Manipulation of Hypercarbia. Blood Cells 5:389-403.
24. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, and Kim SU (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60: 386-392.
25. Peters C, Georgieff MK, Alarcon PAd, Cook RT, Burmeister LF, Lowe LS, and Widness JA (1996) Effect of chronic erythropoietin administration on plasma iron in newborn lambs. Biol Neonate 70:218-228.
26. Reynafarje C, Ramos J, Faura J, and Villavicencio D (1964) Humoral control of erythropoietic activity in man during and after altitude exposure. Proc Soc Exp Biol Med 116:649-658.
27. Sata H, Sugiyama Y, Tsuji A, and Horikoshi I (1996) Importance of receptor-mediated endocytosis in peptide delivery and targeting: kinetic aspects. Adv Drug Delivery Rev 19:445-467.
28. Sawyer ST and Hankins WD (1993) The functional form of the erythropoietin receptor is a 78-kDa protein: correlation with cell surface expression, endocytosis and phosphorylation. Proc Natl Acad Sci USA 90:6849-6853.
29. Sugiyama Y, Kusuhara H, and Siuzuki H (1999) Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J Control Release 62:179-186.
30. Veng-Pedersen P (1977) Curve fitting and modelling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 5:513-531.
31. Veng-Pedersen P (1984) Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions: I. Derivation and theoretical analysis. J Pharmacokinet Biopharm 12:627-648.
32. Veng-Pedersen P (1988) Linear and nonlinear system approaches in pharmacokinetics. How much do they have to offer? J Pharmacokinet Biopharm 16:413-472.
33. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, and Widness JA (2003) A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep. J Pharmacol Exp Ther 306:532-537.
34. Veng-Pedersen P, Chapel S, Schmidt RL, Al-Huniti NH, Cook RT, and Widness JA (2002) An integrated pharmacodynamic analysis of erythropoietin, reticulocyte and hemoglobin responses in acute anemia. Pharm Res 19:1630-1635.
35. Veng-Pedersen P and Gillespie WR (1987) Theorums and implications of a model independent elimination/distribution function decomposition of linear and same nonlinear drug dispositions. III. Peripheral bioavailability computation and clinical implications. J Pharmacokinet Biopharm 17:281-304.
36. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, and Lowe LS (1995) Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 84:760-767.
37. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, and Lowe LS (1999) A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 20:217-223.
38. Widness JA, Garcia JF, Clemons GK, Cavalieri RL, Susa JB, Teramo KA, and Schwartz R (1986) Temporal response of immunoreactive erythropoietin to acute hypoxemia in the sheep fetus. Pediatr Res 20:15-19.
39. Widness JA, Schmidt RL, Veng-Pedersen P, Modi N, and Sawyer ST (1992) A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies. J Lab Clin Med 119:285-294.
40. Wimberley PD, Burnett RW, Covington AK, Foghandersen N, Maas AHJ, Mullerplathe O, Siggardandersen O, and Zijlstra WG (1990) Guidelines for routine measurement of blood hemoglobin oxygen-affinity. Scand J Clin Lab Investig 50:227-234.
41. Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, and Nakano Y (1996) Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239:494-500.
42. Yasada Y, Nagao M, Okano M, Masuda S, Sasaki R, Konishi H, and Tanimura T (1993) Localization of erythropoietin and erythropoietin-receptor in postimplantation mouse embryos. Dev Growth Differ 35:711-722.
43. Yoon WH, Park SJ, Kim IC, and Lee MG (1997) Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 96:227-240.